Alexios Matikas: We show for the first time the superiority of dose dense versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer
Alexios Matikas, Associate Professor of Oncology at Karolinska Institute, shared on LinkedIn:
“Dose dense is the optimal schedule of adjuvant chemotherapy for high risk breast cancer. However, prior trials have mostly compared dose dense regimens to control arms containing the inferior paclitaxel every three weeks regimen. With the phase 3 PANTHER trial (n=2017), just published at the Journal of Clinical Oncology (IF=42.1), we show for the first time the superiority of dose dense chemotherapy over an optimal control of sequential anthracycline and docetaxel.
Big thanks to the Swedish, German and Austrian Breast Cancer Groups, Karolinska University Hospital and Karolinska Institute, all investigators – especially the corresponding author Theodoros Foukakis and the trial’s PI Jonas Bergh, and of course all study participants and their families.
Authors: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis, and Jonas Bergh.
Source: Alexios Matikas/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023